Alecensa (alectinib) / Roche 
Welcome,         Profile    Billing    Logout  
 13 Diseases   52 Trials   52 Trials   3235 News 


«12...4567891011121314...3637»
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
    Journal, HEOR, Real-world evidence, Real-world, Metastases:  Real-World Treatment and Outcomes of ALK-Positive Metastatic Non-Small Cell Lung Cancer in a Southeast Asian Country. (Pubmed Central) -  Jan 21, 2023   
    Patients who received ALK inhibitors as first-line therapy had significantly longer TOT (median of 11 months for first-generation inhibitors, not reached for second-generation inhibitors at the time of analysis) compared to chemotherapy (median of 2 months; P<0.01). Patients on ALK inhibitors had longer median OS and significantly longer TOT compared to chemotherapy, suggesting long-term benefit.
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer, Tagrisso (osimertinib) / AstraZeneca, Alecensa (alectinib) / Roche
    Journal:  Quantitation of osimertinib, alectinib and lorlatinib in human cerebrospinal fluid by UPLC-MS/MS. (Pubmed Central) -  Jan 14, 2023   
    To test the clinical applicability, CSF was collected in seven unique patients using alectinib (n = 1), lorlatinib (n = 2), and osimertinib (n = 4). Measured CSF trough concentrations ranged between 3.37 and 116 ng/mL.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal, HEOR, Metastases:  Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. (Pubmed Central) -  Jan 12, 2023   
    The analysis has considered the overall survival in advanced NSCLC patients treated with the ALK-tyrosine kinase inhibitor (TKI) alectinib...In the sensitivity analysis, the cost-benefit ratio could range from €0.89 to €2.10. The results justify the universal application of ALK diagnosis in advanced NSCLC, which generates a benefit for Spanish society that outweighs its costs and allows optimal treatment with targeted therapies for these patients.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  Alectinib-induced hemolytic anemia. (Pubmed Central) -  Jan 7, 2023   
    Recruiting --> Active, not recruiting Our case demonstrates objective evidence for hemolytic anemia induced by alectinib.
  • ||||||||||  Trial completion date, Trial primary completion date, Tumor mutational burden:  CRAFT: The NCT-PMO-1602 Phase II Trial (clinicaltrials.gov) -  Jan 4, 2023   
    P2,  N=175, Recruiting, 
    Our case demonstrates objective evidence for hemolytic anemia induced by alectinib. Trial completion date: Apr 2024 --> Jun 2025 | Trial primary completion date: Apr 2024 --> Jun 2025
  • ||||||||||  Review, Journal:  Targeted therapy of RET fusion-positive non-small cell lung cancer. (Pubmed Central) -  Dec 31, 2022   
    The RET proto-oncogene is located on the long arm of chromosome 10 with a length of 60,000 bp, and the expression of RET gene affects cell survival, proliferation, growth and differentiation. This review will describe the basic characteristics and common fusion methods of RET genes; analyze the advantages and disadvantages of different RET fusion detection methods; summarize and discuss the recent application of non-selective and selective RET fusion-positive inhibitors, such as Vandetanib, Selpercatinib, Pralsetinib and Alectinib; discuss the mechanism and coping strategies of resistance to RET fusion-positive inhibitors.
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche, Alecensa (alectinib) / Roche
    Trial initiation date, Metastases:  Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK (clinicaltrials.gov) -  Dec 28, 2022   
    P2,  N=30, Not yet recruiting, 
    This review will describe the basic characteristics and common fusion methods of RET genes; analyze the advantages and disadvantages of different RET fusion detection methods; summarize and discuss the recent application of non-selective and selective RET fusion-positive inhibitors, such as Vandetanib, Selpercatinib, Pralsetinib and Alectinib; discuss the mechanism and coping strategies of resistance to RET fusion-positive inhibitors. Initiation date: Sep 2022 --> Jan 2023
  • ||||||||||  Paxlovid (nirmatrelvir and ritonavir) / Pfizer
    Journal:  Overview of Drug-Drug Interactions Between Ritonavir-boosted nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer. (Pubmed Central) -  Dec 27, 2022   
    Drug exposure of RET inhibitors is expected to increase with CYP 3A4 inhibition, with selpercatinib being the least affected...The clinical impact of the DDI between lung cancer TKI and ritonavir-boosted nirmatrelvir vary largely based on the susceptibility of CYP 3A4 inhibition caused by the antiviral. Close monitoring and medication adjustments (i.e., dose changes or alternative COVD-19 therapy) can be employed to overcome DDI to ensure patient safety.
  • ||||||||||  Alecensa (alectinib) / Roche
    Journal:  High incidence and reversible bradycardia events following alectinib initiation. (Pubmed Central) -  Dec 20, 2022   
    Trial completion date: Jan 2023 --> Sep 2023 | Trial primary completion date: Jan 2023 --> Sep 2023 Alectinib-induced bradycardia had a high incidence, appeared relatively early, and was reversible by dose reduction or withdrawal.
  • ||||||||||  Journal, PD(L)-1 Biomarker, IO biomarker:  Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy. (Pubmed Central) -  Dec 17, 2022   
    Then the patient received the sixth line of treatment, camrelizumab/lorlatinib, for 9 antitumor cycles, resulting in PR...To our knowledge, this is the first documented case of cCR in a patient with ALK-positive advanced lung adenocarcinoma treated with multiple lines of therapy followed by surgical treatment. This case reveals the possible survival benefit of immunotherapy after multiple line treatment in ALK-positive advanced lung adenocarcinoma, indicating that it is possible find new therapeutic targets based on NGS molecular detection and provide precise therapeutic strategies for clinical practice when drug resistance or progression occurs in cancer therapy.
  • ||||||||||  Biomarker, Trial completion date, Trial primary completion date:  NRG-LU003: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer (clinicaltrials.gov) -  Dec 7, 2022   
    P2,  N=660, Active, not recruiting, 
    To make an accurate diagnosis and ensure appropriate patient management, it is necessary to be aware of this variant and use proper immunohistochemical stains when facing malignant mesenchymal bone lesions, expanding its differential diagnosis. Trial completion date: Dec 2025 --> May 2023 | Trial primary completion date: Dec 2025 --> May 2023